GSK sells liver disease drug candidate linerixibat to Alfasigma for $690 million. Linerixibat is currently under regulatory review in the US, Europe and China, among other regions. Alfasigma recently completed the acquisition of the Jyselec (filgotinib) business from Galapagos for up to €170 million. The transaction includes 400 employees in 14 European countries and a robust phase 3 program to expand Jyselec's indication. Alfasigma will pay €50 million upfront, potentially €120 million in sales-based milestones and additional payments from European sales. Filgotinib (Jyseleca) is approved for the treatment of moderately to severely active rheumatoid arthritis and ulcerative colitis in the EU, UK and Japan. Michele Manto, former head of commercial operations at Galapagos, will join Alfasigma as head of commercial operations for Western Europe. The transaction strengthens Alfasigma's presence in the gastrointestinal and rheumatology areas.